Predictive Clinical-Biological Markers Over the First 3 Years of Nusinersen Treatment in SMA Type 1 Patients
Werdnig-Hoffmann disease, or type 1 Spinal Muscular Atrophy (SMA), is caused by insufficient SMN protein synthesis due to a genetic defect. Symptoms appear within the first 6 months of life, and without ventilatory support, life expectancy averages 2 years. This study aimed to monitor pNF-H neurofil...
Saved in:
Main Authors: | Mihaela Badina, Andrada Mirea, Corina Sporea, Gabriel Cristian Bejan |
---|---|
Format: | Article |
Language: | English |
Published: |
Romanian Association of Balneology, Editura Balneara
2025-12-01
|
Series: | Balneo and PRM Research Journal |
Subjects: | |
Online Access: | http://bioclima.ro/Balneo754.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evolution of Functional and Paraclinical Markers as Predictive Factors in Pediatric Late-Onset SMA Under Nusinersen Treatment: The Role of CSF pNF-H
by: Mihaela Badina, et al.
Published: (2025-12-01) -
Successful pregnancy of an SMA type 3 sitter on Nusinersen therapy - a case report
by: Miriam Hiebeler, et al.
Published: (2025-01-01) -
Effect of nusinersen on pulmonary function in children with spinal muscular atrophy in the plateau region: A pilot study
by: Jicai Zhu, et al.
Published: (2025-01-01) -
Safety and Efficacy of Nusinersen Focusing on Renal and Hematological Parameters in Spinal Muscular Atrophy
by: Hüseyin Bahadır Şenol, et al.
Published: (2025-01-01) -
Clinicogenetic characterization and response to disease-modifying therapies in spinal muscular atrophy: real-world experience from a reference center in Southern Brazil
by: Ana Letícia Amorim de Albuquerque, et al.
Published: (2025-01-01)